{"id":"NCT01106040","sponsor":"Navidea Biopharmaceuticals","briefTitle":"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","officialTitle":"A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-04","completion":"2011-04","firstPosted":"2010-04-19","resultsPosted":"2013-06-03","lastUpdate":"2013-06-17"},"enrollment":163,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Breast Cancer","Melanoma"],"interventions":[{"type":"DRUG","name":"Lymphoseek","otherNames":["technetium Tc 99m tilmanocept"]}],"arms":[{"label":"Lymphoseek, Lymphatic mapping, Injection","type":"EXPERIMENTAL"}],"summary":"Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.\n\nMulticenter, open-label, within-patient comparative study of Lymphoseek and vital blue dye in the detection of excised lymph nodes in patients with known melanoma and breast cancer. All patients will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and vital blue dye.","primaryOutcome":{"measure":"Concordance of Blue Dye and Lymphoseek","timeFrame":"Surgery after injections of Lymphoseek and blue dye","effectByArm":[{"arm":"Intent-To-Treat","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["23504141","23054107"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":153},"commonTop":[]}}